Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (NASDAQ: SNWV) is a medical technology company that focuses on patented, non-invasive directed energy systems used in advanced wound care and tissue regeneration. Its press releases emphasize research, development, and commercialization of medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures, as well as applications in orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
The SNWV news feed highlights quarterly and annual financial results, including revenue trends, gross margin, operating income, and non-GAAP measures such as EBITDA and Adjusted EBITDA. Investors can follow updates on record quarterly revenues, changes in revenue mix driven by UltraMIST systems and consumables, and management commentary on market conditions in the wound care space.
News items also cover business updates and reimbursement developments. Sanuwave has issued releases discussing proposed and final rules from the Centers for Medicare & Medicaid Services (CMS) for the Physician Fee Schedule, particularly reimbursement for CPT code 97610 associated with UltraMIST procedures. These updates explain how reimbursement levels for physician offices, home visits, long-term care, and hospital settings relate to the company’s expectations.
Additional coverage includes strategic and corporate events, such as a secured credit facility with JPMorgan Chase Bank, N.A. used to refinance a prior debt facility, a license and option agreement related to intravascular shockwave patents, and participation in healthcare industry conferences. The news stream also reports on governance and executive changes disclosed in Form 8-K filings, as well as announcements of conference calls to discuss financial results.
By reviewing the SNWV news page, readers can see how Sanuwave communicates its financial performance, reimbursement environment, capital structure decisions, and ongoing activities in advanced wound care and regenerative medicine.
Sanuwave Health (NASDAQ: SNWV), a provider of FDA-approved wound care products, announced that CEO Morgan Frank will present at the 45th Annual Canaccord Genuity Growth Conference. The presentation is scheduled for August 13, 2025, from 9:30 to 9:55 a.m. ET at the InterContinental Hotel in Boston.
Sanuwave specializes in non-invasive medical systems for regenerative medicine, focusing on skin, musculoskeletal tissue, and vascular structure repair. The company's technology portfolio includes patented energy transfer technologies applied in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Sanuwave Health (NASDAQ:SNWV), a leading provider of FDA-approved wound care products, reported preliminary Q2 2025 revenues of $10.1-$10.2 million, marking its highest Q2 revenue in company history. This represents a 41-42% increase compared to Q2 2024.
The company has undergone significant commercial expansion, including the appointment of a new head of sales and commercial operations. By July, Sanuwave will have 13 sales representatives covering all national territories, plus a dedicated national accounts manager for larger opportunities. The first half of 2025 showed strong performance with a 50-51% revenue increase compared to the first half of 2024.
Full Q2 2025 results will be released around August 8th, 2025.
Sanuwave Health (NASDAQ: SNWV), a provider of non-invasive wound care solutions, has been selected for inclusion in the Russell 2000® Index as part of the 2025 Russell indexes reconstitution, effective June 30. The company will also be included in the broader Russell 3000® Index and Russell Microcap® Index.
The Russell indexes, which capture the 4,000 largest U.S. stocks by market capitalization, are widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked to these indexes as of June 2024. Membership in these indexes remains in place for one year.
Sanuwave Health specializes in regenerative medicine products for wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions through their patented energy transfer technologies.
Sanuwave Health (NASDAQ:SNWV) has appointed Greg Bazar to its Board of Directors. Bazar brings extensive experience in engineering, computer science, cybersecurity, AI, and business intelligence. He currently serves as Chairman of Simpatico Systems and was previously instrumental at 3D-P, leading to its acquisition by Epiroc. The appointment comes as board member Michael Stolarski steps down, though he will remain as a consultant to assist with the transition.
Bazar's appointment aligns with Sanuwave's focus on interdisciplinary leadership and its evolution beyond therapeutics into informational ecosystems. His background in technology and cybersecurity is expected to contribute to the company's future roadmap in wound care solutions.
Sanuwave Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss their Q1 2025 financial results on Friday, May 9, 2025, at 8:30 AM ET.
Investors can access the call through toll-free (1-800-245-3047) or international (1-203-518-9765) numbers using Conference ID: SANUWAVE. Materials will be available on the company's investor website, and a replay will be accessible until May 30, 2025, using the replay access ID: 11158734.
SANUWAVE Health (NASDAQ: SNWV) reported preliminary Q1 2025 revenues of $9.1-9.3 million, marking the highest Q1 revenue in company history. This represents a 57-61% increase compared to Q1 2024.
The company's UltraMIST product line showed exceptional performance with a 65% growth versus Q1 2024, contributing to approximately 99% of total revenues. The strong performance came despite a transition period involving new sales leadership and sales force restructuring.
The company manufactures all UltraMIST systems and applicators domestically, insulating it from current tariff concerns. Full Q1 2025 results are expected to be released around May 9, 2025.
SANUWAVE Health (NASDAQ: SNWV) reported record-breaking financial results for Q4 and full year 2024. Q4 revenues reached $10.3 million, up 47% year-over-year, with a gross margin of 77.9%. Full-year 2024 revenues hit $32.6 million, increasing 60% from 2023.
Key Q4 highlights include:
- 135 UltraMist® systems sold (up from 79 in Q4 2023)
- UltraMist® consumables revenue grew 59% to $5.9 million
- Operating income of $2.5 million, up 143%
- Adjusted EBITDA of $3.7 million
For 2025, SANUWAVE projects Q1 revenue of $8.4-9.0 million (45-55% YoY growth) and full-year revenue guidance of $48-50 million (47-53% growth). The company completed a 1-for-375 reverse stock split and raised $10.3 million through private placement in Q4 2024.
SANUWAVE Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss its Q4 and Full Year 2024 financial results. The call will take place on March 21, 2025, at 8:30 AM ET.
Investors can access the call through toll-free (1-800-245-3047) or international (1-203-518-9765) numbers using Conference ID: SANUWAVE. Supporting materials will be available on the company's investor relations website. A replay of the call will be accessible through April 11, 2025, using the replay access ID: 11157832.
FAQ
What is the current stock price of Sanuwave Health (SNWV)?
What is the market cap of Sanuwave Health (SNWV)?
